Best Practice & Research Clinical Haematology
Volume 24, Issue 4 , Pages 509-514 , December 2011

Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?

  • Richard M. Stone, MD, Professor of Medicine (Director)

      Affiliations

    • Harvard Medical School, Boston, MA 02215, USA
    • Adult Leukemia Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, M1b-17, Boston, MA 02215, USA
    • Corresponding Author InformationTel.: +1 617 632 2214; Fax: +1 617 632 2933.

References 

  1. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood. 2011;117:2577–2584
  2. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29:475–486
  3. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27:5168–5174
  4. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Onc. 2011;11:543
  5. San Miguel JF, Vidriales MG, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to post induction treatment stratification. Blood. 2001;98:1746–1751
  6. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet Study. J Clin Oncol. 2009;27:5195–5201
  7. McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations including cuplike blast morphology. Arch Patho Lab Med. 2010;8:1143–1151
  8. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116:2295–2303
  9. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712–715
  10. Miyamote T, Nagafuji K, Harada M, et al. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Leuk Lymphoma. 1997;25(1–2):69–75
  11. Morschhauser F, Cayuela JM, Martini S, et al. Evaluation of minimal residual disease using reverse transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol. 2000;18:788–794
  12. Corbacioglu A, Scholl C, Schlenk R, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010;28:3724–3729
  13. Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21:4413–4422
  14. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. Blood. 1997;90:1321–1325
  15. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27:3650–3658
  16. Walter RB, Gooley RA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29:1190–1197

PII: S1521-6926(11)00086-7

doi: 10.1016/j.beha.2011.09.006

Best Practice & Research Clinical Haematology
Volume 24, Issue 4 , Pages 509-514 , December 2011

Article Tools

* Image Usage & Resolution